Skip to main content

Bilateral blindness secondary to optic nerve ischemia from severe amlodipine overdose: a case report



Calcium channel blockers are commonly prescribed medications; calcium channel blocker overdose is becoming increasingly prevalent. The typical presentation of a calcium channel blocker overdose is hypotension and decreased level of consciousness. We describe a case of a calcium channel blocker overdose that led to bilateral cortical blindness, a presentation that has not previously been reported.

Case presentation

A 49-year-old white woman with known bilateral early optic atrophy presented to our hospital with hypotension and obtundation following a known ingestion of 150 mg of amlodipine. She was transferred to our intensive care unit where she was intubated, mechanically ventilated, and required maximal vasopressor support (norepinephrine 40 mcg/minute, epinephrine 40 mcg/minute, and vasopressin 2.4 units/hour) along with intravenously administered crystalloid boluses. Despite these measures, she continued to deteriorate with persistent hypotension and tachycardia, as well as anuria.

Intralipid emulsion therapy was subsequently administered to which no initial response was observed. A chest X-ray revealed diffuse pulmonary edema; intravenous diuresis as well as continuous renal replacement therapy was initiated.

Following the initiation of continuous renal replacement therapy, her oxygen requirements as well as urine output began to improve, and 3 days later she was liberated from mechanical ventilation. Following extubation, she complained of new onset visual impairment, specifically seeing only red-green colors, but no objects. An ophthalmologic examination revealed that this was due to bilateral optic atrophy from prolonged hypotension during the first 24 hours after the overdose.


Persistent hypotension in the setting of a calcium channel blocker overdose can lead to worsening optic atrophy resulting in bilateral cortical blindness.

Peer Review reports


Calcium channel blockers (CCBs) are commonly prescribed cardiovascular medications, used in the treatment of hypertension, angina pectoris, cardiac arrhythmias, migraine headaches, and some circulatory conditions such as Raynaud’s syndrome. CCB toxicity, caused by intentional or unintentional overdose, has devastating systemic effects. According to the 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System, 16% of all cardiovascular drug exposures were due to CCBs, however, this class of drugs accounted for 38% of deaths [1].

CCB overdose is known to be associated with hypotension and decreased level of consciousness. A case report from 1992 describes a female who developed a stroke, a rare complication, after a verapamil overdose [2]. To the best of our knowledge, this is the first reported case of bilateral cortical blindness following a severe CCB overdose.

Case presentation

A 49-year-old white woman was brought to our emergency department (ED) after an intentional overdose with 150 mg of amlodipine, 60 mg of escitalopram, and 6 mg of risperidone. Her past medical history included hepatitis C from a blood transfusion in 1993, remote intravenous drug use, diverticulitis, hypertension, mild chronic obstructive pulmonary disease, gastroesophageal reflux disease, anxiety, and depression. She was also seen by the ophthalmology service in 2007 with regards to declining visual acuity, secondary to early optic atrophy.

She was seen by family to be normal at 11:00 on the day of admission to our hospital, and was subsequently found by family members to have an altered level of consciousness at 13:50, at which point the emergency services were called.

Upon arrival to our ED at 14:00, she was found to be hypotensive with a blood pressure of 84/38 mmHg, tachycardia with a heart rate of 117 beats/minute, and obtunded with a Glasgow Coma Scale (GCS) of 9/15. She was immediately intubated for airway protection, placed on a cardiac monitor, and an arterial and central venous catheter was inserted. The initial resuscitation consisted of a bolus 2 liters of crystalloid administered intravenously, 2 g of calcium gluconate administered intravenously, 5 mg of glucagon administered intravenously, 1 ampule of dextrose 50% in water (D50W) administered intravenously followed by 70 units of bolus short-acting insulin administered intravenously followed by 70 units/hour infusion. She was also given 50 g of activated charcoal via a nasogastric tube for gastric decontamination. The Critical Care team was notified, and she arrived in our Intensive Care Unit at 14:30. Upon arrival, she required 30 mcg/minute of norepinephrine, 30 mcg/minute of epinephrine, and 2.4 units/hour of vasopressin to maintain a mean arterial pressure greater than 65 mmHg.

A point-of-care transthoracic echocardiogram was performed at 17:00 to evaluate her profound shock, which demonstrated an under-filled hyperdynamic left ventricle (Fig. 1). There was no right ventricle (RV) dilatation, and RV systolic function was intact. This finding was indicative of a severe vasodilatory state causing her shock, as opposed to cardiogenic shock. We began aggressive administration of intravenously administered boluses with crystalloid fluids infused through a Level 1 rapid infuser. Initially, she improved hemodynamically with each 1 L bolus, demonstrating that she was preload-dependent in the setting of her vasoplegia. Her catecholamine requirements decreased significantly, norepinephrine 40 mcg/minute and epinephrine 40 mcg/minute to 25 mcg/minute and 10 mcg/minute, respectively, after a total of 23 liters of intravenously administered crystalloid boluses were given. She was maintained on the vasopressin 2.4 units/hour throughout the resuscitation process.

Fig. 1
figure 1

Point-of-care transthoracic echocardiogram subcostal short-axis views. a Short-axis view of the left ventricle at the level of the papillary muscles reveals the left ventricle initially in diastole, b followed by mid-systole, and c in late systole. Symmetric contraction of the left ventricle is appreciated until near obliteration of the left ventricle cavity in late systole, which is indicative of a hyperdynamic and under-filled left ventricle

Despite continuous repletion of potassium with intravenously administered potassium chloride and orally administered potassium chloride, she developed refractory hypokalemia with associated changes on the electrocardiogram (ECG; Fig. 2). She also required intravenously administered dextrose boluses despite a 10% dextrose infusion. Given the hypokalemia and hypoglycemia that were becoming problematic to treat, the decision was made to abandon hyperinsulinemic-euglycemia therapy in this patient, as she did not appear to have a strong component of insulin resistance.

Fig. 2
figure 2

A 12-lead electrocardiogram demonstrating features of hypokalemia including increased amplitude and width of the P-waves, T-wave flattening and inversion, ST depression, and prominent U wave formation best seen in the precordial leads. Apparent QTc prolongation is observed due to fusion of the T and U waves. BPM breaths per minute, ECG electrocardiogram

She was mechanically ventilated on assist-control ventilation with a respiratory rate of 18 breaths/minute, pressure control ventilation at 19 cmH2O, positive end-expiratory pressure (PEEP) 5 cmH20, and fraction of inspired oxygen (FiO2) 40% with oxygen saturation of 94%. Following 23 liters of fluid resuscitation, her oxygenation requirements greatly increased due to the volume overload causing significant pulmonary edema. Her mechanical ventilation requirements increased to assist-control ventilation rate of 27 breaths/minute, pressure control 36 cmH2O, PEEP 14 cmH20, and FiO2 100% to maintain oxygen saturation in the mid 80%. A portable chest radiograph confirmed that she had diffuse pulmonary edema (Fig. 3) and she remained anuric. At 22:15, the nephrology service was consulted to initiate continuous renal replacement therapy (CRRT) for volume overload. At approximately 22:35, we discontinued administration of intravenously administered fluid boluses, minimized all intravenously administered fluid input, and administered a 200 mg bolus of intravenously administered furosemide. She had a good response and her urine output increased to 100 to 225 mL/hour. At 22:50 she continued to deteriorate with low blood pressure, tachycardia, and we proceeded to administer to her 1.5 mL/kg of 20% lipid emulsion therapy, to which she did not initially respond.

Fig. 3
figure 3

Portable anterior-posterior chest X-ray revealing diffuse bilateral opacities in keeping with pulmonary edema

The cardiovascular surgery service was also consulted to assess the potential need for veno/venous extracorporeal membrane oxygenation (ECMO). At 23:30, the CRRT was started and she responded very well and ultimately did not require ECMO. At 00:30, her oxygenation status began to improve, with oxygenation saturation >90% on 100% FiO2. From 00:30 to 10:30, she had gradual and complete reversal of her shock state. She was slowly weaned off all vasopressors, and continued to make urine after an initial 8 hours of complete anuria postadmission. By 13:00 the following day, she was off CRRT, with a urine output up to 500 ml/hour, thought to be secondary to post-acute tubular necrosis (ATN) diuresis. Her oxygen requirements continued to decrease and by 10:15 she was requiring 60% FiO2 to maintain an oxygen saturation of 96 to 98%.

On clinical examination, she continued to recover and demonstrated no persisting organ dysfunction. Three days after admission, she was extubated and liberated from mechanical ventilation. She was alert and oriented, but complained of new onset visual impairment, specifically only seeing red and green colors, but unable to see any objects. Of importance, her visual acuity was relatively intact prior to admission with the exception of the stable optic atrophy. The remaining neurologic examination was otherwise normal. A magnetic resonance imaging (MRI) of her brain showed a few small foci of high signal on the diffusion-weighted image (DWI) sequence in her right frontal and parietal lobes consistent with acute infarcts (Fig. 4a). These may have been from emboli to the right middle cerebral artery (MCA) territory. Alternatively, these may be deep watershed infarcts between the anterior cerebral artery (ACA) and MCA territories. In addition, both optic nerves were mildly thickened with high signal on DWI and fluid-attenuated inversion recovery (FLAIR), consistent with cytotoxic edema from infarction (Fig. 4b, c). A lumbar puncture was performed which showed an elevated opening pressure (18 mmHg), but otherwise normal cerebrospinal fluid, and no evidence of central nervous system (CNS) vasculitis. Subsequent ophthalmologic evaluation revealed she had no light perception bilaterally despite best corrected vision, no light response, and mid-dilated pupils bilaterally. The intraocular pressure of her right and left eyes was 14 mmHg and 16 mmHg, respectively. Examination of the anterior segment was unremarkable bilaterally. Posterior segment examination revealed no evidence of disc edema, hemorrhage, retinitis, or vasculitis bilaterally.

Fig. 4
figure 4

Magnetic resonance imaging of patient’s brain. a Axial diffusion-weighted image demonstrating small strokes to the right frontal and parietal lobes (white arrows). b and c are axial diffusion-weighted image and fluid-attenuated inversion recovery image demonstrating bilateral optic nerves thickening and increased signal compatible with ischemic injury (white arrows)

Both ophthalmology and neuroradiology concluded that her blindness was probably due to optic nerve injury from the prolonged hypotension during the first 24 hours after the overdose. She was discharged from hospital 8 days postadmission in a stable condition; however, she was still burdened by binocular blindness. She was subsequently seen by ophthalmology as an out-patient; an examination again revealed no light perception in both eyes and complete nonreactivity to both pupils, consistent with complete optic atrophy suggesting severe optic nerve damage.


Cardiovascular medications were the seventh most common class of drug exposure reported to poison control centers of the USA in 2014 [3]. The 2014 annual report of the American Association of Poison Control Centers’ National Poison Data System identified 3.96% of cases with multi-substance exposure and 2.36% due to single substance exposures. Cardiovascular medication overdose accounted for the second and third highest number of fatalities in multi-substance and single substance exposures, respectively [3]. Of importance, this drug class had the fourth greatest increase in serious exposures per year from 2000 to 2014 [3]. CCB overdose has been proportionally less common than other cardiovascular medications, such as beta-blockers. In 2002, CCBs accounted for only 16% of cardiovascular medication exposures, while causing 38% of fatalities of this drug class [1]. This emphasizes the lethality of CCB overdose, as well as the importance of discussing individual cases to better understand the physiology and individual drug effects on a case-by-case basis.

CCBs are used in a variety of clinical settings to treat hypertension, angina pectoris, Raynaud’s syndrome, migraine headaches, and tachyarrhythmias [4]. CCBs can be subdivided into two major categories based on their predominant physiologic effects. The dihydropyridines (amlodipine, nifedipine, felodipine, nimodipine) preferentially block the L-type calcium channels in the peripheral vasculature. This results in vasodilatory effects without significant effect on cardiac contractility or chronotropy. The nondihydropyridines (verapamil, diltiazem) inhibit the transmembrane influx of calcium into myocardial fibers and pacemaker cells, with relatively little effect on vascular smooth muscle cells [5]. Amlodipine is structurally related to nifedipine, although it differs because of the presence of a basic amino side chain in the 2 position of the dihydropyridine ring [5]. Of interest, this amino group is positively ionized at physiologic pH, which may account for the unique properties of this CCB. In general, CCBs are characterized by high rates of clearance, low volumes of distribution, and short half-lives. On the other hand, pharmacokinetic studies of amlodipine have revealed it to possess a high volume of distribution and a low rate of elimination [5]. In addition, amlodipine is highly protein-bound and metabolized primarily by the liver [4]. There is also a dose-dependent change in pharmacokinetic clearance from first-order to zero-order clearance by the liver [6]. Overall, this results in a prolonged half-life of up to 30 hours for amlodipine, which is in stark contrast to the half-life of 1 to 2 hours for first-generation CCBs [5]. When tailoring a treatment plan, it is important to consider the wide variability in drug clearance and extent of toxicity in each individual patient based on exposure level and liver function.

Our patient ingested 150 mg of amlodipine, and arrived at our ED within 3.5 hours of ingestion. She received appropriate decontamination therapy with 50 g of activated charcoal after establishment of a definitive airway via endotracheal intubation. She exhibited cardiovascular collapse upon arrival to our ED, which manifested the severity of her exposure to CCB. Because of the dihydropyridine toxicity, she was hypotensive with a normal to marginally elevated heart rate, which was not an appropriate compensation for her shock state. Throughout her hospitalization, she did not require treatment of bradycardia or myocardial dysfunction. Standard treatment was provided upon arrival at our ED including intravenously administered crystalloid fluids, intravenously administered calcium gluconate, intravenously administered glucagon, intravenously administered insulin, and intravenously administered dextrose all in bolus form. Intravenously administered glucagon is controversial in CCB overdose, while it is well established for the treatment of beta-blocker overdose. This is due to its mechanism of increasing cyclic adenosine monophosphate (cAMP) and contraction of smooth muscle via a beta-receptor independent pathway [7]. It is, therefore, of questionable usefulness in CCB overdose mechanistically [4].

Hyperinsulinemia-euglycemia therapy has been utilized in the setting of CCB and beta-blocker overdose. There is evidence that this therapy improves hemodynamics in human observational studies [8], human case series [9,10,11,12], and animal studies [13,14,15,16]. The mechanism of action is incompletely understood, but CCBs appear to disrupt fatty acid metabolism and create relative insulin resistance within the myocardium. This is complicated by the impaired ability of the pancreatic beta-islet cell to secrete insulin via exocytosis, which is dependent on calcium influx. The high-dose insulin infusion is believed to partially compensate for this insulin-resistant state, by promoting carbohydrate delivery to the myocardium [17, 18]. Our patient received an initial intravenously administered bolus of 70 units of regular insulin, along with 50 g of dextrose intravenously administered. This was followed by an infusion of regular insulin at 70 units/hour. The typical dosing is 1 unit/kg of regular insulin bolus with 0.5 g/kg dextrose push, followed by 0.5 to 1 unit/kg per hour of regular insulin [19]. Refractory hypokalemia and hypoglycemia added further complication to the treatment of our patient, and the decision was made to abandon hyperinsulinemic-euglycemia therapy. There was no appreciable hemodynamic consequence to the discontinuation of this therapy indicating no significant component of insulin resistance.

As described above, amlodipine toxicity would be expected to have profound peripheral vasodilatory effects, while relatively sparing myocardial contractility and chronotropy. This was confirmed using point-of-care transthoracic echocardiography. The parasternal views revealed a hyperdynamic left ventricle, with under-filling and almost complete obliteration of her left ventricular cavity on short-axis view. This provided reassurance that there was no cardiogenic component to her shock state, and that cardiovascular collapse through profound peripheral vasodilatation was the primary component. Our decision to begin aggressive intravenously administered crystalloid resuscitation using a Level 1 rapid infuser was primarily to avoid systemic hypothermia. In the setting of profound vasodilatation, our patient was already predisposed to heat loss and hypothermia.

Intravenously administered lipid emulsion has been used in the setting of CCB overdose with mixed results, and there remains a great deal of controversy regarding its benefit. While its efficacy in the setting of amlodipine toxicity is poorly elucidated, it is reasonable to administer as rescue therapy in the setting of cardiac arrest due to CCB toxicity or during refractory shock and cardiovascular collapse [20,21,22]. We administered 1.5 mL/kg of 20% lipid emulsion as an intravenously administered bolus, as described previously [20, 23, 24]. There have also been studies using higher doses (6.2 to 18.6 mL/kg), although these were animal models [19]. In our patient, the administration of lipid emulsion therapy resulted in impaired laboratory monitoring due to gross lipemia and hemolysis, without immediate improvement in the hemodynamics. Specifically, serum potassium and lactate, as well as international normalized ratio/partial thromboplastin time (INR/PTT) became unreliable. It is important to note that there is evidence for up to three repeated doses, especially during cardiac arrest [19], and so it is possible we under-dosed our patient and we also did not continue a lipid emulsion infusion following the initial bolus. However, our patient started to show a remarkable resolution of her cardiovascular shock state over the next 12 hours following administration of the lipid emulsion therapy. Of interest, there is evidence for delayed hemodynamic improvement following lipid emulsion therapy of 10 hours in one case report [21]. In our case, we do not believe lipid emulsion therapy, at the limited dose provided, played a significant role in her recovery, although true causality cannot be established definitively.

Our patient’s dramatic recovery from her vasodilatory shock due to amlodipine overdose was a combination of our initial aggressive resuscitation, reversal of the anuric state, and fluid removal by means of CRRT. All organ dysfunction resolved, and she was successfully extubated during her third day of hospitalization. It became apparent at that time that she was having significant distress due to loss of vision bilaterally. She was previously documented to have mild optic atrophy with visual acuity of 20/40 bilaterally upon ophthalmology assessment as an out-patient in December 2007. Considering she described mild red and green images and no ability to perceive objects, this was a significant change from her baseline. Neuroimaging via MRI of her head revealed subtle cortical infarcts in her right frontal and parietal lobes, but would not explain her apparent blindness. Cerebral infarcts, while rare, have been described secondary to CCB overdose in the literature [2, 25]. Magnetic resonance angiography of her head and neck did reveal acute infarction of her optic nerves bilaterally, as well as the possibility of CNS vasculitis due to irregularities of the M2 and M3 branches of both MCAs. The differential for these findings included primary vasculitis or secondary causes, including drug overdose. Historically, drug-induced CNS vasculitis has been seen in the setting of cocaine or methamphetamine overdose [26,27,28]. Of importance, our patient did not exhibit any signs and symptoms of systemic vasculitis. An alternative explanation could be due to profound vasoconstriction caused by the high doses of norepinephrine and epinephrine that were required to support her. Of interest, reversible cerebral vasoconstriction syndrome (RCVS) has been described previously in the setting of epinephrine administration [29]. RCVS is a relatively rare clinical and radiological syndrome encompassing a diverse group of disorders leading to reversible vasoconstriction of the cerebral arteries. This vasoconstriction can be spontaneous or exogenously driven. The use of vasoactive drugs accounts for approximately 50% of cases in most published series [30]. While the pathogenesis is largely unknown, dysregulation of cerebral vascular tone may be induced by sympathetic overactivity, endothelial dysfunction, and oxidative stress. This is further supported by the significant overlap between RCVS and posterior reversible encephalopathy syndrome (PRES) [30]. Of interest, our patient did have focal stenosis of an M2 branch of her right MCA, with accompanying irregularities of several other M2 and M3 branches identified on MRI within several days of her presentation. A follow-up study with MRA of her head and neck 17 days later revealed no further M2 stenosis and resolution of described vascular abnormalities. Given the generally benign course of RCVS and reversibility within 12 weeks of onset, it is possible an element of RCVS was present, although it would not specifically explain focal and bilateral optic nerve infarction in our patient.

Our literature search failed to identify any previous case reports or retrospective studies of outcome data that describe blindness in the setting of CCB overdose. In this case report, we describe the first incident of blindness in a patient with CCB overdose. Overall, the most likely explanation for this patient’s bilateral blindness was probably multifactorial. She had a predisposed condition of bilateral optic atrophy at baseline. This had certainly progressed, since her original assessment in 2007. She was in a profound state of shock upon admission, and this could theoretically have caused significant hypoperfusion to smaller vessels supplying the optic nerves. Blindness secondary to systemic hypotension has been described previously in the literature, and is often due to profound or recurrent blood loss [31]. In general, culprit lesions are located within the parietal or occipital lobes in the setting of systemic hypotension, by means of infarctions in the border zones between cerebral arteries, or due to diffuse cerebral cortical neuronal death [31, 32]. Other mechanisms for visual loss after hypotension include juxtalaminar optic nerve infarction in the setting of atherosclerosis, and orbital optic nerve infarction due to compression from hypoxic edema [31, 32]. When optic nerve infarcts are present without the finding of watershed infarcts, a secondary underlying factor must be present to cause vulnerability within the optic nerves. Other case reports have identified localized atherosclerosis or severe anemia as a secondary risk factor. In our patient, the pre-existing optic nerve atrophy led to vulnerability of the optic nerves for infarction in the setting of systemic hypotension.

An important condition to consider is anterior ischemic optic neuropathy (AION), which is characterized by a sudden loss of vision due to optic nerve head ischemia. Infarction of the short posterior ciliary artery supplying the optic nerve head is believed to be the culprit, causing ischemia, edema, and compartment syndrome [33]. AION is subdivided into arteritic (10%) and non-arteritic (90%) causes [34]. Non-arteritic AION (NAAION) occurs in the setting of compromised blood flow associated with several comorbidities including hypertension, tobacco smoking, hypercholesterolemia, atherosclerosis, and diabetes mellitus [33, 34]. An anatomically small or “crowded” disc has also been identified as a risk factor [33]. The clinical presentation includes painless visual loss and swelling of the optic disc, followed by pallor. NAAION can present with visual loss upon waking, due to nocturnal hypotension [33]. NAAION typically involves unilateral visual loss, but 14.7% of patients over a 5-year follow-up period in the ischemic optic neuropathy (ION) decompression trial progressed to second eye involvement [35]. In most cases of hypotension-induced NAAION, bilateral visual loss occurs simultaneously or within weeks of the initial unilateral symptoms [33]. NAAION has also been described in patients undergoing chronic renal replacement therapy, but is largely underdiagnosed in this population [33, 34, 36]. Of interest, not only patients undergoing intermittent hemodialysis are at risk. In a case report by Al-Kaabi et al., a 5-year-old child undergoing continuous peritoneal dialysis (CPD) for a period of 4 years developed acute bilateral vision loss upon waking from sleep [34]. In this patient, frequent systemic hypotensive episodes and one instance of PRES had required previous hospitalization. A funduscopic examination was consistent with NAAION, and anemia, uremia, as well as infiltrative optic neuropathy and other intracranial causes were ruled out. The resulting diagnosis was NAAION caused by hypotension-induced low perfusion and ischemia of the optic nerve [34]. Vidal and Schaefer reviewed the occurrence of AION in infants, and found it to occur in 1% of children on CPD [36]. Risk factors in this population included very young age, autosomal recessive polycystic kidney disease, and sustained hypotension [36]. While poor visual outcomes have been reported among both children and adults undergoing CPD diagnosed with NAAION, the primary treatment remains reversal of hypotension and optimization of optic nerve perfusion [34]. Steroid therapy has also been shown to provide some therapeutic effect, although it remains controversial [37,38,39].

NAAION due to hypotensive insult is not isolated to those undergoing chronic renal replacement therapy. Kim et al. published a case report on a 50-year-old man following a lumbar laminectomy, with subsequent prolonged immobilization for a 3-month period [40]. Upon sitting upright for the first time since his operation, he experienced significant orthostatic hypotension. Within several hours, he developed acute visual loss and was ultimately diagnosed with NAAION by means of optic disc filling delay on fluorescein angiography [40]. Of interest, he was also found to be anemic, a known secondary risk factor for the development of NAAION [33]. Partial recovery of vision was noted in this patient upon 6-month follow-up, although the visual fields remained severely constricted [40].

Perioperative vision loss (POVL) following prone spine surgery has been described in the literature, occurring in 0.013 to 1% of cases [41]. While AION has been identified in some cases, other causes include posterior ischemic optic neuropathy (PION), central retinal artery occlusion, central retinal vein occlusion, cortical blindness, direct compression, acute angle closure glaucoma, epidural spine injections, and other less common factors [41]. In terms of AION in this setting, identified risk factors include prolonged operative times, long-segment spinal instrumentation, anemia, intraoperative hypotension, diabetes, obesity, male sex, greater estimated blood loss, microvascular pathology, and decreased percent colloid administration [41].

Hypotension-induced NAAION can also occur following acute blood loss and in patients prescribed medications such as phosphodiesterase type 5 inhibitors and interferon-α [34, 42, 43]. In terms of hemorrhagic shock, NAAION can result from both spontaneous and traumatic blood loss [31, 40, 44,45,46]. Reported outcomes have ranged from some degree of vision recovery in 50% of patients, while 10 to 15% of patients experienced complete recovery of vision [40]. Overall, hypotension-induced NAAION could help explain the pathophysiology of bilateral vision loss in our patient, although a definitive diagnosis would have required further diagnostic testing in the setting of chronic optic atrophy.

The high doses of vasopressors required in this case may have had more pronounced local effects in some smaller vessels, which could render structures like the optic nerves more vulnerable to infarction. The description above of RCVS does support cerebral vasoconstriction in the setting of vasoactive medications, although MRI revealed unilateral reversible stenosis of only the right MCA branches in our patient. While direct ischemia of the optic nerves has not previously been described in the setting of CCB overdose, ischemia within other structures is well described in the literature. Above, we described case reports of cerebral infarction following CCB overdose. Other case reports and retrospective analyses have described bowel ischemia and renal ischemia due to high-dose vasopressor use in the setting of CCB overdose [47, 48].

Our patient was seen in follow-up by her ophthalmologist as an out-patient 5 months’ post-discharge. Unfortunately, her vision measured no light perception bilaterally without pupillary reaction to light. She was diagnosed as having complete optic atrophy suggestive of severe optic nerve damage which was felt to be irreversible.


In the setting of a CCB overdose causing persistent severe hypotension secondary to profound vasodilatory shock, multiple high-dose vasopressors support for the cardiovascular collapse can lead to worsening of existing optic atrophy resulting in bilateral blindness.



Anterior cerebral artery


Anterior ischemic optic neuropathy


Acute tubular necrosis


Cyclic adenosine monophosphate


Calcium channel blocker


Central nervous system


Continuous peritoneal dialysis


Continuous renal replacement therapy


Dextrose 50% in water


Diffusion-weighted image




Extracorporeal membrane oxygenation


Emergency department

FiO2 :

Fraction of inspired oxygen


Fluid-attenuated inversion recovery


Glasgow Coma Scale


International normalized ratio/partial thromboplastin time


Ischemic optic neuropathy


Middle cerebral artery


Magnetic resonance angiography


Magnetic resonance imaging


Non-arteritic anterior ischemic optic neuropathy


Positive end-expiratory pressure


Posterior ischemic optic neuropathy


Perioperative vision loss


Posterior reversible encephalopathy syndrome


Reversible cerebral vasoconstriction syndrome


Right ventricle


  1. Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rutherfoord Rose S, et al. 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2003;21:353–412.

    Article  PubMed  Google Scholar 

  2. Shah AR, Passalacqua BR. Case report: sustained-release verapamil overdose causing stroke: an unusual complication. Am J Med Sci. 1992;304:357–9.

    Article  CAS  PubMed  Google Scholar 

  3. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol. 2015;53:962–1147. Available from:

    Article  CAS  Google Scholar 

  4. Burkes R, Wendorf G. A multifaceted approach to calcium channel blocker overdose: a case report and literature review. Clin Case Rep. 2015;3:566–9. Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  5. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol. 1994;73(3):2A–9A.

    Article  CAS  PubMed  Google Scholar 

  6. McAllister RJ, Hamann S, Blouin R. Pharmacokinetics of calcium-entry blockers. Am J Cardiol. 1985;55:30B–40B.

    Article  CAS  PubMed  Google Scholar 

  7. Walter FG, Frye G, Mullen JT, Ekins BR, Khasigian PA. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med. 1993;22:1234–7.

    Article  CAS  PubMed  Google Scholar 

  8. Greene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33:2019–24.

    Article  CAS  PubMed  Google Scholar 

  9. Holger JS, Stellpflug SJ, Cole JB, Harris CR, Engebretsen KM. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol (Phila). 2011;49:653–8.

    Article  CAS  Google Scholar 

  10. Boyer EW, Duic PA, Evans A. Hyperinsulinemia/euglycemia therapy for calcium channel blocker poisoning. Ped Emerg Care. 2002;18:36–7.

  11. Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med. 2001;344:1721–2.

  12. Yuan TH, Ii WPK, Tomaszewski CA, Ford MD, Kline JA. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37:463–74.

    Article  CAS  PubMed  Google Scholar 

  13. Engebretsen KM, Morgan MW, Stellpflug SJ, Cole JB, Anderson CP, Holger JS. Addition of phenylephrine to high-dose insulin in dihydropyridine overdose does not improve outcome. Clin Toxicol (Phila). 2010;48:806–12.

    Article  CAS  Google Scholar 

  14. Kline JA, Raymond RM, Leonova ED, Williams TC, Watts JA. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34:289–98.

    Article  CAS  PubMed  Google Scholar 

  15. Kline JA, Leonova E, Williams TC, Schroeder JD, Watts JA. Myocardial metabolism during graded intraportal verapamil infusion in awake dogs. J Cardiovasc Pharmacol. 1996;27:719–26.

    Article  CAS  PubMed  Google Scholar 

  16. Kline J, Tomaszewski C, et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993;267:744–50. Available from:

    CAS  PubMed  Google Scholar 

  17. Kline JA, Raymond RM, Schroeder JD, Watts JA. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol. 1997;145:357–62. Available from:

    Article  CAS  PubMed  Google Scholar 

  18. Bechtel LK, Haverstick DM, Holstege CP. Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway. Acad Emerg Med. 2008;15:368–74.

    Article  PubMed  Google Scholar 

  19. St-Onge M, Dube PA, Gosselin S, Guimont C, Godwin J, Archambault PM, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol. 2014;52:926–44. doi:10.3109/15563650.2014.965827.

    Article  CAS  Google Scholar 

  20. Sirianni AJ, Osterhoudt KC, Calello DP, Muller AA, Waterhouse MR, Goodkin MB, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008;51:412–5.

    Article  PubMed  Google Scholar 

  21. Doepker B, Healy W, Cortez E, Adkins EJ. High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and beta-blocker overdose: a case series. J Emerg Med Elsevier Ltd. 2014;46:486–90. Available from:

    Article  Google Scholar 

  22. Bologa C, Lionte C, Coman A, Sorodoc L. Lipid emulsion therapy in cardiodepressive syndrome after diltiazem overdose – case report. Am J Emerg Med. 2013;31:1154. e3-4. Available from:

    Article  PubMed  Google Scholar 

  23. Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation. 2009;80:591–3.

    Article  CAS  PubMed  Google Scholar 

  24. Gueret G, Pennec JP, Arvieux CC. Hemodynamic effects of intralipid after verapamil intoxication may be due to a direct effect of fatty acids on myocardial calcium channels. Acad Emerg Med. 2007;14:761.

    Article  PubMed  Google Scholar 

  25. Samniah NN. Cerebral infarction associated with oral verapamil overdose. J Toxicol Clin Toxicol. 1988;26:365–9.

    Article  CAS  PubMed  Google Scholar 

  26. Matick H, Anderson D, Brumlik J. Cerebral vasculitis associated with oral amphetamine overdose. Arch Neurol. 1983;40:253–4.

    Article  CAS  PubMed  Google Scholar 

  27. White SRS. Amphetamine toxicity. Semin Respir Crit Care Med. 2002;23:27–36.

    Article  PubMed  Google Scholar 

  28. Raso AMA. Vascular pathology of surgical interest in drug addicts. Minerva Cardioangiol. 2000;48:287–96.

    CAS  PubMed  Google Scholar 

  29. Palma J-A, Fontes-Villalba A, Irimia P, Garcia-Eulate R, Martinez-Vila E. Reversible cerebral vasoconstriction syndrome induced by adrenaline. Cephalalgia. 2012;32:500–4. doi:10.1177/0333102412444011.

    Article  PubMed  Google Scholar 

  30. Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: Epidemiology, pathogenesis, and clinical course. Am J Neuroradiol. 2015;36:1392–9. Available from:

    Article  CAS  PubMed  Google Scholar 

  31. Johnson MW, Kincaid MC, Trobe JD. Bilateral retrobulbar optic nerve infarctions after blood loss and hypotension: a clinicopathologic case study. Ophthalmology. 1987;94:1577–84.

    Article  CAS  PubMed  Google Scholar 

  32. Chopra KB, Banka NH, Chandalia HB. Bilateral optic nerve infarction following acute systemic hypotension and anemia – a case report. Indian J Ophthalmol. 1992;40:66–9.

    CAS  PubMed  Google Scholar 

  33. Bansal S, Ansons A, Vishwanath M. Hypotension-induced blindness in haemodialysis patients. Clin Kidney J. 2014;7:387–90.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Al-Kaabi A, Haider A, Shafeeq M, El-Naggari M, El-Nour I, Ganesh A. Bilateral anterior ischaemic optic neuropathy in a child on continuous peritoneal dialysis: case report and literature review. Sultan Qaboos Univ Med J. 2016;16:e504–507. Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  35. Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002;134:317–28.

    Article  PubMed  Google Scholar 

  36. Vidal E, Schaefer F. Hypotension in infants on chronic peritoneal dialysis: mechanisms, complications, and management. Adv Perit Dial. 2015;31:54–8.

  37. Swartz NG, Beck RW, Savino PJ, Sergott RC, Bosley TM, Lam BL, et al. Pain in anterior ischemic optic neuropathy. J Neuro-Ophthalmol. 1995;15:9–10. Available from:

    Article  CAS  Google Scholar 

  38. Hayreh SS. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Surv Ophthalmol. 2010;55:399–400. Available from:

    Article  PubMed  Google Scholar 

  39. Rebolleda G, Pérez-López M, Casas-Llera P, Muñoz-Negrete FJ. Treatment of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefe’s Arch Clin Exp Ophthalmol. 2013;251:1031–2.

    Article  Google Scholar 

  40. Kim J-Y, Kim K-N, Kim W-J, Lee Y-H. Acute bilateral visual loss related to orthostatic hypotension. Korean J Ophthalmol. 2013;27:372–5. Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  41. Epstein NE. Perioperative visual loss following prone spinal surgery: a review. Surg Neurol Int. 2016;7:S347–60. Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  42. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol. 2005;25:9–13. Available from:

    Article  PubMed  Google Scholar 

  43. Lohmann CP, Kroher G, Bogenrieder T. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet. 1999;353(9161):1326.

    Article  CAS  PubMed  Google Scholar 

  44. Hayreh SS. Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology. 1987;94:1488–502. Available from:

    Article  CAS  PubMed  Google Scholar 

  45. Chisholm IA. Optic neuropathy of recurrent blood loss. Br J Ophthalmol. 1969;53:289–95. Available from:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Klewin KM, Appen RE, Kaufman PL. Amaurosis and blood loss. Am J Ophthalmol. 1978;86:669–72. Available from:

    Article  CAS  PubMed  Google Scholar 

  47. Levine M, Curry SC, Padilla-Jones A, Ruha A-M. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: A 25-year experience at a single center. Ann Emerg Med. 2013;xx:1–7. Available from:

    Google Scholar 

  48. Chan TBS, Chan YC, Lau FL. Ischemia complications after calcium channel blocker poisoning. Ann Emerg Med. 2014;63:90. Available from:

    Article  PubMed  Google Scholar 

Download references


Not applicable.


Not applicable.

Availability of data and materials

The datasets used in this case report are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations



YL wrote the discussion, GC wrote the abstract and presentation, AL reviewed the MRI images and modified the manuscript, RK reviewed and modified the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Raymond Kao.

Ethics declarations

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kao, R., Landry, Y., Chick, G. et al. Bilateral blindness secondary to optic nerve ischemia from severe amlodipine overdose: a case report. J Med Case Reports 11, 211 (2017).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: